Sample-wise outlier kinases in ERBB2-positive breast cancer cell lines

Slides:

Advertisements

Similar presentations

Homozygous deletions within chromosome 9q23.

Advertisements

Supplemental Material

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

سرطان الثدي Breast Cancer

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

A. D. B. C. - ΔNP63α - β-Actin IMEC - SUM MDA-MB IMEC

PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.

H3K4me3 pattern association with functionally relevant genes and changes over time. H3K4me3 pattern association with functionally relevant genes and changes.

Genomic alterations in breast cancer cell line MDA-MB-231.

Copy-number alterations in an archival breast cancer sample.

ECM 29 and Kaplan–Meier survival curves for additional datasets

(A-B) Expression of dominant negative p73. (C) Knockdown of p73

Chromosome 8 cDNA microarray gene expression profile of the amplified regions of 8p11–12 in SUM-44, -52, and -225 cells versus MCF10A HME control cells.

Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.

USP2a regulates MYC expression through the MDM2–p53 axis.

CREB1 promotes the induction of endogenous ERα target genes.

A, IC50 dose–response curves of SYD985, T-DM1, and ADC isotype control in all USC cell lines tested in vitro (i.e., HER2 3+ cell lines, P =

SW fraction induces S phase arrest and apoptosis.

(A) Relative expression levels of the top most down-regulated genes in LATS2L breast tumors (TCGA-BRCA dataset, see Fig 1) in the panel of breast cancer.

The influence of SHIP2 on cell migration in breast cancer cells.

CD151-knockdown cells show an aberrant spreading response to PMA

PKM2 is tyrosine phosphorylated and inhibited by FGFR1 in cancer cells with oncogenic or overexpressed FGFR1. PKM2 is tyrosine phosphorylated and inhibited.

Cytotoxic activity of HER2-lytic hybrid peptide.

CDCP1 is required for invadopodia formation and ECM degradation by human breast cancer cells. CDCP1 is required for invadopodia formation and ECM degradation.

CDCP1 colocalizes and interacts with MT1-MMP.

coTCRcys-transduced T cells control tumor growth in vivo.

Validation of the screen hits.

Integrated mRNA and microRNA expression and DNA methylation clusters.

In vitro invasion assays were done in the Chemicon invasion chamber containing extracellular matrix. In vitro invasion assays were done in the Chemicon.

Protein expression profile in a dasatinib-resistant cell line.

Selective delivery of pIC/PPHAffibody decreases the survival of HER2-overexpressing cells. Selective delivery of pIC/PPHAffibody decreases the survival.

Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by.

Matriptase-2 inhibited breast tumor development in vivo.

The effects of IAA and glycyrrhizin (Gc) on proliferation and cell-cycle distribution. The effects of IAA and glycyrrhizin (Gc) on proliferation and cell-cycle.

FGFR3 mutation analysis of a selection of urine samples from patients included with an FGFR3-mutant (MT) tumor. FGFR3 mutation analysis of a selection.

A, one-step viral growth curves: RT treatment increased the virus yield in MV-CEA–treated U87 cells by up to 2 log as compared with MV-CEA infection only.

Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases. Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases.

Active AR signaling in enzalutamide-resistant xenograft tumors.

EN1-associated chromatin complexes in breast cancer cells.

EN1 expression in breast cancer and clinical outcome.

Biological effects of BRAF silencing: growth curves of A375 (A) and ARO (B) cell lines in the absence or presence of doxycycline. Biological effects of.

Comparison of variant associations from previous reports and results from the KP GWAS meta-analysis for 105 known prostate cancer risk SNPs. Plotted values.

PD-L1 is expressed in breast cancer.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

Clustering analysis of DTC-associated genes.

Pancreatic adenocarcinoma, chronic pancreatitis, and normal pancreas samples can be distinguished on the basis of gene expression profiling. Pancreatic.

FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung cancer cell lines. FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung.

Kaplan–Meier curves for RFS and OS by various marker groups.

Untargeted LC/MS metabolite profiling of DFMO-treated HT-29 colorectal cancer cells. Untargeted LC/MS metabolite profiling of DFMO-treated HT-29 colorectal.

Individual treatment outcomes of 20 patients treated with afatinib and 12 patients treated with afatinib and trastuzumab. Individual treatment outcomes.

Transcriptional activity and growth of mutant ER in a breast cancer cell line. Transcriptional activity and growth of mutant ER in a breast cancer cell.

ROC analysis of MIC-1 and CA19-9.

Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.

A and B, linearity of the preamplification step shown by a similar expression pattern of ERα mRNA in four breast tumor samples pre– and post–linear amplification.

siRNA screen validation.

Trastuzumab resistance siRNA screen identifies PPM1H.

Survival, subsequent therapies, and response.

G34 H3K36me3 upregulates MYCN which is selectively targetable by kinases that destabilize the protein. G34 H3K36me3 upregulates MYCN which is selectively.

Depleting NQO1 expression levels inhibits growth of NSCLC cells in soft agar. Depleting NQO1 expression levels inhibits growth of NSCLC cells in soft agar.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

FGF19 amplification in liver cancer cell lines is associated with response to NVP-BGJ398. FGF19 amplification in liver cancer cell lines is associated.

NVP-BGJ398 inhibits proliferation of a subset of cancer cell lines.

Driver pathways and key genes in OSCC

Integrated analysis of gene expression and copy number alterations.

I3C reduces the level of Cdc25A protein in breast cancer cells.

Comparison of shRNA scoring approaches.

Fig. 3 Gene expression analysis in 48-plex drug treatment experiments.

Silencing E4BP4 abrogates the promoting effect of SMAD3 knockdown on IFNγ production in NK-92 cells. Silencing E4BP4 abrogates the promoting effect of.

Presentation transcript:

Sample-wise outlier kinases in ERBB2-positive breast cancer cell lines. Sample-wise outlier kinases in ERBB2-positive breast cancer cell lines. Left, the scatter plots display kinome expression profiles of individual breast cancer cell lines. Kinases with (red/pink) and without (green) outlier expression that were targeted for knockdown are shown in color. Labels in black denote additional kinases with outlier expression. Right, growth curves show the effect of targeting outlier (ERBB2) versus nonoutlier (RPS6KB1) kinases in ZR-75-30 cells and the effects of trastuzumab and/or knockdown of the outlier FGFR4 in CAMA-1, MDA-MB-361, and MDA-MB-453 cells. Values represent mean ± SD. **, P < 0.01; ****, P < 0.0001. Vishal Kothari et al. Cancer Discovery 2013;3:280-293 ©2013 by American Association for Cancer Research